Is Solventum’s 8% Rally in 2025 the Start of a Rebound?

Simply Wall St.

Oct 26

If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578555636"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578555636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578555636?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2025-10-26 12:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578555636","market":"sg","top_or_hot":-1,"title":"Is Solventum’s 8% Rally in 2025 the Start of a Rebound?","media":"Simply Wall St.","content":"<div>\n<p>If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/is-solventums-8-rally-in-2025-the-start-of-a-rebound\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Solventum’s 8% Rally in 2025 the Start of a Rebound?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Solventum’s 8% Rally in 2025 the Start of a Rebound?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-26 12:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/is-solventums-8-rally-in-2025-the-start-of-a-rebound><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/is-solventums-8-rally-in-2025-the-start-of-a-rebound\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/is-solventums-8-rally-in-2025-the-start-of-a-rebound","article_id":"2578555636","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/is-solventums-8-rally-in-2025-the-start-of-a-rebound","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2578555636","pubTimestamp":1761452973,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with more conviction. That kind of flat performance can frustrate momentum seekers, but for the valuation-conscious, it might hint at opportunity or a story that is still developing.\nDigging a bit into the recent price action, Solventum is up a healthy 8.4% so far this year, quickly bouncing back from...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","SOLV":"Solventum"},"translate_title":"Solventum 2025年8%的上涨是反弹的开始吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"SOLV":1.5},"content_text":"If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with more conviction. That kind of flat performance can frustrate momentum seekers, but for the valuation-conscious, it might hint at opportunity or a story that is still developing. Digging a bit into the recent price action, Solventum is up a healthy 8.4% so far this year, quickly bouncing back from the uncertainty that briefly weighed on the stock last year. Some investors have pointed to the company’s recent moves in streamlining its business and rolling out targeted initiatives in its core sectors as a reason why market perceptions seem to be shifting. The risk profile appears to be stabilizing and growth potential is back in focus. However, the modest 1% dip over the last week reflects a little ongoing wariness, as the market waits for more evidence that these efforts will deliver sustained value. On the valuation front, Solventum currently scores a 2 out of 6 on our value checklist, indicating it appears undervalued in only two of the six core metrics we track. That leaves plenty worth debating about whether now is the right time to buy, hold, or move on from the stock. Next up, we will break down those six valuation checks, what they mean in real terms, how Solventum stacks up, and why the full story might not be found in numbers alone. Solventum scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Solventum Discounted Cash Flow (DCF) Analysis The Discounted Cash Flow (DCF) model is a forward-looking valuation approach that estimates a company's true worth by projecting its future cash flows and discounting them back to their present value. For Solventum, this means making educated assumptions about how much cash the business will generate in the coming years and determining what that is worth today. Currently, Solventum reports free cash flow of $236.8 million. Analysts forecast strong growth in the near term and project annual cash flows to increase steadily over the next several years. By 2028, free cash flow is expected to reach $968 million. Beyond the 5-year analyst window, further growth estimates are extrapolated. Looking out to 2035, projections indicate free cash flows approaching $1.75 billion. All these figures are calculated in U.S. dollars. Rolling all these forecasts together, the DCF model arrives at an intrinsic value for Solventum stock of $120.69 per share. This is roughly 40.8% above where the stock trades today. According to this model, the current market price may reflect a meaningful undervaluation. Result: UNDERVALUED Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Solventum. SOLV Discounted Cash Flow as at Oct 2025 Our Discounted Cash Flow (DCF) analysis suggests Solventum is undervalued by 40.8%. Track this in your watchlist or portfolio, or discover more undervalued stocks. Approach 2: Solventum Price vs Earnings (P/E Ratio) The Price-to-Earnings (P/E) ratio is a widely used valuation measure for profitable companies because it reflects how much investors are willing to pay for a dollar of earnings. It offers a straightforward way to compare profitability and market expectations across firms in the same sector. Growth expectations and risk play a major role in shaping what is considered a normal or fair P/E ratio. Companies with stronger earnings growth or lower risk are typically rewarded with higher P/E ratios, as investors anticipate bigger or more consistent future profits. Solventum currently trades at a P/E ratio of 32.6x, which is a bit richer than both the industry average of 29.7x and its peer group at 28.4x. Simply Wall St's proprietary Fair Ratio for Solventum is 32.2x. This represents the multiple the stock would deserve based on factors such as its earnings growth outlook, profit margins, size, risks, and its positioning within the medical equipment industry. The Fair Ratio is especially helpful because it goes deeper than a basic comparison to sector peers or broad industry averages. It considers Solventum’s own financial health, growth prospects, and risk profile. This means you get a more tailored and accurate sense of what the stock should be worth right now. With the actual P/E (32.6x) just slightly above the Fair Ratio (32.2x), there is minimal disconnect between price and fundamentals. Solventum appears to be fairly valued on this metric. Result: ABOUT RIGHT NYSE:SOLV PE Ratio as at Oct 2025 PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Solventum Narrative Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is your concise, story-driven perspective on what really matters for a company, connecting your knowledge or outlook on Solventum with your assumptions about its future revenue, earnings, and margins. Narratives turn complex numbers into a personal forecast, bridging a company’s evolving story, your own financial projections, and what you think is a fair price. Simply Wall St makes this powerful, research-backed tool accessible to everyone on the Community page, where millions of investors update and share their Narratives in real time as new news and earnings data emerge. By creating and tracking your own Solventum Narrative, you can see how your estimated fair value compares to the current share price, helping you decide when it might be time to buy, hold, or sell. For example, some Solventum Narratives see strong restructuring and international product launches as catalysts for robust future growth and set a fair value as high as $103 per share, while others emphasize lingering transition risks and set their fair value closer to $73 per share. Your view and your Narrative may land anywhere in between, guiding your decisions with both facts and context. Do you think there's more to the story for Solventum? Create your own Narrative to let the Community know! NYSE:SOLV Community Fair Values as at Oct 2025  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}